Sage Therapeutics Announces Brexanolone Accomplishes Primary Achievements in Both Phase 3 Clinical Trials in Postpartum Depression

12:01 11/09/2017

A biopharmaceutical company manufacturing innovative medicines to treat life-changing central nervous system (CNS) disorders SAGE  announced positive results from two Phase 3 trials with its formulation of brexanolone.

Brexanolone delivered a quick and durable reduction in depressive symptoms over a 30-day trial measured by HAM-D in both placebo-controlled multi-center trials.

Patients treated with brexanolone confirmed significant symptom reductions and the drug was generally well endured and displayed a similar safety profile as seen in earlier studies.

Postpartum depression (PPD) is a common biological complication of childbirth affecting women typically beginning in the third trimester of pregnancy or within four weeks after giving birth.

PPD is estimated to affect approximately 10-20% of women giving birth in the U.S. and more than half of these occasions may go undiagnosed without proper screening.

Dr. Samantha Meltzer-Brody, M.D., associate professor and director of UNC Perinatal Psychiatry Program said, “PPD is commonly viewed as a disorder solely experienced by the mother, but it also seriously impacts the child and family members – both immediate and extended.”

“Symptoms of PPD should not be overlooked by new moms of those in their support networks and the healthcare community should encourage discussion and appropriate action,” Meltzer-Brody added.

Shares of Sage Therapeutics SAGE  surged 54.8% this morning after the release of the results.

The results of the surge in price is recorded as a new 52-week high for SAGE  and a new 5 year high for their share prices.

This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read